Results 21 to 30 of about 4,117 (197)

Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross-Sectional Population-Based Analysis. [PDF]

Int J Dermatol
Prurigo nodularis patients face a significant burden of comorbidities, necessitating a comprehensive approach to care. We aimed to explore the association between prurigo nodularis, its comorbid conditions, and healthcare usage patterns.BACKGROUNDPrurigo
Valdman-Grinshpoun Y, Zaga A, Cohen AD, Schonmann Y, Czarnowicki T.   +4 more
europepmc   +2 more sources

Dupilumab for recalcitrant prurigo nodularis: Case report

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Joel Reis, Inês Raposo, Manuela Selores
doaj   +1 more source

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial [PDF]

Dermatology and Therapy
Introduction Prurigo nodularis (PN) is a chronic inflammatory dermatosis with severe, persistent pruritus and limited effective therapies. Janus kinase (JAK) inhibition has emerged as a targeted strategy for PN.
Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, Hongzhong Jin   +28 more
doaj   +2 more sources

Successful Treatment of Pediatric Atopic Prurigo Nodularis with Dupilumab [PDF]

Clinical, Cosmetic and Investigational Dermatology
Yuping Zhang,* Lizhu Liang,* Chen Li Department of Dermatology, Zhongshan City People’s Hospital, Zhongshan City, Guangdong Province, 528403, People’s Republic of China*These authors contributed equally to this workCorrespondence:
Zhang Y, Liang L, Li C
doaj   +2 more sources

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. [PDF]

, 2023
BACKGROUND Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. METHODS
Fleischer, Alan, Staender, S., Nahm, Walter K, Nahm, Walter, Legat, Franz J, Lynde, C., Sauder, M., Nahm, W.K., Lynde, Charles, Sauder, Maxwell, Laquer, Vivian T., Barbarot, Sebastien, Kwatra, Shawn, OLYMPIA 2 Investigators, [missing], Ständer, Sonja, Serra-Baldrich, E., Lapeere, Hilde, Legat, F.J., Gharib, Rola, De Bruin-Weller, Marjolein S., Szepietowski, J. C., Jabbar Lopez, Z.K., Lapeere, H., Simon, D., Kwatra, Shawn G, Piketty, C., Gharib, R., Reich, A., Szepietowski, Jacek C., Laquer, V. T., De Bruin-Weller, M. S., Ahmad, F., Nahm, Walter K., Jabbar Lopez, Zarif, Naldi, Luigi, Laquer, V.T., de Bruin-Weller, Marjolein, Barbarot, S., Misery, L., Szepietowski, Jacek C, Paul, Carle, Ständer, S., Fleischer, A., Serra-Baldrich, Esther, Szepietowski, Jacek, Kwatra, S.G., Jabbar Lopez, Zarif K., Laquer, Vivian, Jabbar Lopez, Zarif K, Naldi, L., Kwatra, Shawn G., Lopez, Z. K. Jabbar, Conrad, Curdin, Reich, Adam, Yosipovitch, G., Paul, C., Szepietowski, J.C., Ahmad, Faiz, Legat, Franz J., De Bruin-Weller, Marjolein S, Kwatra, S. G., Legat, F. J., Yosipovitch, Gil, Piketty, Christophe, Misery, Laurent, Laquer, Vivian T, Conrad, C., Legat, Franz, Nahm, W. K., Simon, Dagmar, De Bruin-Weller, M.S.   +70 more
core   +2 more sources

Prurigo nodularis, prurigo chronica új terápiás lehetőségei [PDF]

, 2021
Prurigo nodularis (PN) is a skin disease that develops on chronically itchy skin. There are various causes behind the chronic itch. Due to intensive research in recent years different mechanisms that can participate in the development of chronic pruritus
Csörgő Sándorné Bata Zsuzsanna
core   +1 more source

Upadacitinib for prurigo nodularis

JAAD Case Reports
Clara Muntaner-Virgili, MD, Carlos Moreno-Vilchez, MD, Clara Torrecilla-Vall-Llossera, MD, Ignasi Figueras-Nart, MD   +3 more
doaj   +3 more sources

Oral Alitretinoin for Patients with Refractory Prurigo

Medicina, 2020
Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging.
Bo Young Chung, Ji Young Um, Seok Young Kang, Min Je Jung, Jin Cheol Kim, In-Suk Kwak, Chun Wook Park, Hye One Kim   +7 more
doaj   +1 more source

Tofacitinib for Prurigo Nodularis: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Changlan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology,
Peng C, Li C, Zhou Y, Wang Q, Xie P, Li T, Hao P   +6 more
doaj  

Out‐of‐pocket expenditures in adult patients with prurigo nodularis in France

JEADV Clinical Practice, 2023
Background Chronic prurigo or prurigo nodularis is a severe condition with chronic pruritus and skin lesions. Current unnmet medical needs are numerous and generate a significant burden for the patients.
Laurent Misery, Christine Patras deCampaigno, Denis Jullien, Adrien Marquie, Sylvie Gabriel, Charles Taieb, Carle Paul   +6 more
doaj   +1 more source